How Investors Are Reacting To Amicus Therapeutics’ (FOLD) Shift to GAAP Profitability and Revenue Beat

• Amicus Therapeutics reported that for the quarter ended September 30, 2025, it achieved GAAP profitability with net income of US$17.31 million and total revenues of US$169.06 million, surpassing analyst expectations and marking a turnaround from a net loss a year ago.
• Strong commercial growth for Galafold and Pombiliti + Opfolda, along with positive progress in its late-stage pipeline and new reimbursement agreements, underpin the company’s confidence in achieving continued revenue expansion and long-term financial strength.
• We will explore how Amicus Therapeutics’ move to GAAP profitability shapes its investment narrative and growth outlook moving forward.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 36 companies in the world exploring or producing it. Find the list for free.

Amicus Therapeutics Investment Narrative Recap

Shareholders in Amicus Therapeutics need to believe that strong global uptake of Galafold and Pombiliti + Opfolda, paired with commercial discipline and a maturing pipeline, can drive sustainable profitability and reduce reliance on a few key products. The milestone of achieving GAAP profitability is a clear short-term catalyst, but the company’s heavy revenue concentration continues to pose the most significant risk if demand falters or competitors gain ground. Based on the latest news, this impact does not materially alter the risk of revenue concentration in the near term.

Among the recent announcements, the reiteration of earnings guidance for 2025 stands out. Management’s confidence in total revenue growth of 15% to 22% and positive GAAP net income in the second half of 2025 provides context for the company’s profitability progress, a key driver for investor sentiment given historical net losses and ongoing concerns over product dependency.

However, even as profits emerge, investors should be aware that heightened competition in rare diseases could quickly shift market share, particularly if...

Read the full narrative on Amicus Therapeutics (it's free!)

Amicus Therapeutics is projected to reach $995.5 million in revenue and $234.9 million in earnings by 2028. This outlook assumes annual revenue growth of 20.3% and an earnings increase of $273 million from the current earnings of $-38.1 million.

Uncover how Amicus Therapeutics' forecasts yield a $15.60 fair value, a 75% upside to its current price.

Exploring Other Perspectives

Four Simply Wall St Community members estimated fair value for Amicus Therapeutics, with projections from US$13.96 to US$58.16 per share. While market participants see strong commercial momentum, heavy product concentration remains a key challenge for future stability, explore these contrasting viewpoints for more insight.

Explore 4 other fair value estimates on Amicus Therapeutics - why the stock might be worth just $13.96!

Build Your Own Amicus Therapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Amicus Therapeutics research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Amicus Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amicus Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Find companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 25 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com